Search Result

Pathways Recommended:	Immunology/Inflammation

Results for "

Parkinson’s disease. Inflammation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (1) Interleukin Related (1) LRRK2 (1) MAGL (1) NOD-like Receptor (NLR) (1) P-glycoprotein (1) PROTACs (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (3) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W230975

(E/Z)-Piperine (E/Z)-Bioperine; (E/Z)-1-Piperoylpiperidine	Cytochrome P450 P-glycoprotein	Neurological Disease Inflammation/Immunology Cancer
(E/Z)-Piperine ((E/Z)-Bioperine) is an alkaloid with a pungent property. (E/Z)-Piperine shows anti-inflammation, immunomodulatory and anti-cancer, antispasmodic and anti-secretory effects. (E/Z)-Piperine demonstrates significant neuroprotective effect in Alzheimer’s disease and Parkinson’s disease .

HY-156438

Ruvonoflast NT-0796	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease
Ruvonoflast (NT-0796) is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. Ruvonoflast inhibits IL-1β release in human PBMC cells with an IC₅₀ value of 0.32 nM. Ruvonoflast is an isopropyl ester that undergoes intracellular conversion to Ruvonoflast, the carboxylic acid active species. Ruvonoflast reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. Ruvonoflast is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .

HY-150702

MAGLi 432	MAGL	Neurological Disease Inflammation/Immunology
MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC₅₀ values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease .

HY-178797

PROTAC LRRK2 Degrader-3	PROTACs LRRK2	Neurological Disease Inflammation/Immunology
PROTAC LRRK2 Degrader-3 is a PROTAC LRRK2 degrader with a DC₅₀ of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation. (Pink: LRRK2 ligand: LRRK2-IN-19 (HY-177016); Black: Linker (HY-178830); Blue: E3 ligand (HY-163927); E3+Linker (HY-178828)) .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library	1,787 compounds
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD. MCE offers a unique collection of 1,787 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Anti-Parkinson's Disease Compound Library

1,787 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,787 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

(E/Z)-Piperine (E/Z)-Bioperine; (E/Z)-1-Piperoylpiperidine	Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants Piper nigrum Linn.	Cytochrome P450 P-glycoprotein
(E/Z)-Piperine ((E/Z)-Bioperine) is an alkaloid with a pungent property. (E/Z)-Piperine shows anti-inflammation, immunomodulatory and anti-cancer, antispasmodic and anti-secretory effects. (E/Z)-Piperine demonstrates significant neuroprotective effect in Alzheimer’s disease and Parkinson’s disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks